title: Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.
abstract: Survival rates determined at diagnosis are often too negative for cancer survivors. Conditional relative survival reflects actual prognosis during follow-up better. Data from all 54,015 patients newly diagnosed in the Netherlands with B-cell non-Hodgkin lymphoma during 1989-2008, aged 15-89 years (Netherlands Cancer Registry), were used. Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diagnosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for survivors of indolent B-cell non-Hodgkin lymphoma improved slightly with each additional year survived up to 91%. For patients with aggressive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and gradually thereafter to 93% after 16 years. There were differences between morphological entities. Initial differences in conditional relative survival at diagnosis between groups with different disease stages became smaller with increasing number of years survived. Age remained a prognostic indicator, also after prolonged follow-up. These results help caregivers to plan optimal surveillance and inform patients about their actual prognosis during follow-up. Long-lasting excess mortality among patients with B-cell non-Hodgkin lymphoma indicates the need for additional care long after their diagnosis.
authors.affiliation: research@ikz.nl.
authors.forename: Saskia A M
authors.initials: SA
authors.lastname: van de Schans
authors.forename: Liza N
authors.initials: LN
authors.lastname: van Steenbergen
authors.forename: Jan Willem W
authors.initials: JW
authors.lastname: Coebergh
authors.forename: Maryska L G
authors.initials: ML
authors.lastname: Janssen-Heijnen
authors.forename: Dick Johan
authors.initials: DJ
authors.lastname: van Spronsen
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
references.citation: Eur J Cancer. 2005 May;41(7):1051-7
references.pmid: 15862755
references.citation: Ann Oncol. 2007 Aug;18(8):1408-13
references.pmid: 17693654
references.citation: Ann Oncol. 2012 Jan;23(1):171-182
references.pmid: 21464157
references.citation: Ann Oncol. 2012 May;23(5):1280-1286
references.pmid: 21948810
references.citation: Ann Oncol. 2009 Oct;20(10):1697-702
references.pmid: 19549712
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3159-65
references.pmid: 18591554
references.citation: Med J Aust. 2011 Jan 17;194(2):73-7
references.pmid: 21241220
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Cancer. 1996 Nov 1;78(9):2004-10
references.pmid: 8909323
references.citation: Lancet Oncol. 2006 Aug;7(8):668-75
references.pmid: 16887484
references.citation: Int J Cancer. 2008 Oct 15;123(8):1917-23
references.pmid: 18688859
references.citation: Int J Cancer. 2007 May 15;120(10):2196-201
references.pmid: 17285582
references.citation: Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4
references.pmid: 21908504
references.citation: Eur J Cancer. 2004 Nov;40(16):2494-501
references.pmid: 15519525
references.citation: J Clin Oncol. 2004 May 15;22(10):1864-71
references.pmid: 15143078
references.citation: Ann Hematol. 1999 Jul;78(7):315-9
references.pmid: 10466443
references.citation: J Clin Oncol. 2010 May 20;28(15):2520-8
references.pmid: 20406936
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3035-40
references.pmid: 12915592
references.citation: Cancer. 2002 Apr 1;94(7):2015-23
references.pmid: 11932904
references.citation: Br J Haematol. 2005 Jun;129(5):597-606
references.pmid: 15916681
references.citation: Am J Epidemiol. 2006 Oct 1;164(7):689-96
references.pmid: 16840519
references.citation: Health Rep. 2011 Jun;22(2):21-5
references.pmid: 21848129
references.citation: Blood. 2004 Sep 1;104(5):1258-65
references.pmid: 15126323
references.citation: Cancer. 2006 May 15;106(10):2165-70
references.pmid: 16586498
references.citation: Curr Treat Options Oncol. 2006 Jul;7(4):270-5
references.pmid: 16916487
references.citation: Ann Oncol. 2006 Apr;17(4):709-12
references.pmid: 16418307
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v175-6
references.pmid: 20555074
references.citation: Acta Oncol. 2010;49(1):3-12
references.pmid: 19714523
references.citation: Haematologica. 2010 Sep;95(9):1503-9
references.pmid: 20494934
references.citation: J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7
references.pmid: 8089863
references.citation: Eur J Cancer. 2007 Jan;43(2):391-401
references.pmid: 17134891
references.citation: Haematologica. 2013 Mar;98(3):479-86
references.pmid: 22929981
references.citation: Cancer Treat Rep. 1977 Sep;61(6):1023-7
references.pmid: 902260
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v181-3
references.pmid: 20555076